From BioHealth Investor
Biotechnology
TERCICA INC [TRCA] +20.49%
CERUS CORP [CERS] +18.04%
LPATH INC [LPTN.OB] +15.38%
AURIGA LABORATORIES [ARGA.OB] +11.20%
EMERGENT BIOSOLUTION [EBS] +8.54%
Diagnostic Substances
PRESSURE BIOSCIENC [PBIO] +10.68%
ICAGEN, INC. [ICGN] +9.44%
ORCHID CELLMARK INC [ORCH] +5.33%
AVIGEN INC [AVGN] +3.72%
IMMUNOMEDICS INC [IMMU] +3.68%
Drug Delivery
COLUMBIA LABS INC [CBRX] +4.13%
BIOPROGRESS PLC [BPRG] +3.02%
FLAMEL TECH SA ADR [FLML] +2.77%
HOSPIRA INC [HSP] +2.44%
ELAN CP PLC ADR [ELN] +2.35%
Drug Manufacturers
NEXMED INC [NEXM] +5.88%
REGENERX BIOPHARM IN [RGN] +4.19%
SUPERGEN INC [SUPG] +3.97%
ISIS PHARM INC [ISIS] +3.88%
YM BIOSCIENCES INC [YMI] +3.33%
Medical Appliances & Equipment
ENDOCARE INC [ENDO.OB] +15.00%
THERAGENICS CORP [TGX] +6.28%
MICRUS ENDOVASCULAR [MEND] +5.56%
MEDICALCV INC [MCVI.OB] +5.00%
CYNOSURE, INC. [CYNO] +4.85%
Medical Instruments & Supplies
CPC OF AMERICA INC [CPCF.OB] +12.46%
IMMUNOCELLULAR THERA [IMUC.OB] +11.63%
MILESTONE SCIENTIFIC [MLSS.OB] +10.00%
ENDOLOGIX INC [ELGX] +8.16%
STRATEGIC DIAGNOST [SDIX] +6.97%
Medical Laboratories & Research
AETERNA ZENTARIS [AEZS] +3.62% $221.9 M
OSI PHARMACEUTIC [OSIP] +2.63% $2.0 B
ALLIANCE IMAGING INC [AIQ] +2.60% $531.8 M
ERESEARCHTECHNOLOG [ERES] +1.49% $632.6 M
MEDTOX SCIENTFIC INC [MTOX] +1.28%
http://www.biohealthinvestor.com/
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
